ProKidney Corp. (PROK) shares continued their downward trajectory, plunging 5.02% in pre-market trading on Friday. This decline follows a significant 5.41% drop during Thursday's regular trading session, as investors react to a reiterated Sell rating from a major financial institution.

Bank of America Securities analyst Jason Gerberry maintained a Sell rating on ProKidney and set a remarkably low price target of $1.00. This bearish outlook from a prominent Wall Street firm has evidently shaken investor confidence, contributing to the sharp decline in ProKidney's stock value over the past 24 hours. The analyst's pessimistic view suggests serious concerns about the company's future prospects and potential financial performance.

The reaffirmation of the Sell rating and the low price target could have far-reaching implications for ProKidney Corp. It may lead to increased scrutiny of the company's business model, financial health, and growth prospects. As the negative sentiment persists, ProKidney may need to address these concerns and provide a clear strategy to regain market confidence. Investors and other analysts might reassess their positions on PROK stock, potentially leading to further volatility in the near term.